SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Infinity Pharmaceuticals
INFI 0.0160-4.8%Sep 29 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LJM who wrote (51)7/27/2006 4:09:56 PM
From: Mike McFarland  Read Replies (3) of 210
 
You wonder if Kosan will walk away from their
17-aag, fall back to their epothilone program.

Holtzman says they have a better drug, and I
have to believe it, well I don't have to, but
I want to. The bit about solubility rings true
and sounds very plausible, to me.

I still have not bought the Chiosis paper
Overall, these characteristics propose Hsp90 as an important target of whose inhibition may aim at a wide-range of oncogenic transformations. Several years into Hsp90 research have shed light into the feasibility, but also the limitations, of such an approach.

So, what are the limitations? Anybody read the paper?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News